Core Insights - Kane Biotech Inc. has achieved significant regulatory milestones that enhance its wound care platform and commitment to high-quality medical device development [1] Regulatory Approvals - The company has received FDA 510(k) clearance for its revyve Antimicrobial Skin and Wound Cleanser, which is designed for the cleansing and moistening of various acute and chronic dermal lesions, including pressure ulcers and diabetic foot ulcers [2] - This clearance validates Kane's expanded revyve product line, which targets wound bacteria and biofilms, key factors in delayed healing and antibiotic resistance [2] Certification Expansion - Kane has expanded its ISO 13485:2016 certification under the Medical Device Single Audit Program (MDSAP) to include distribution and wound cleansers, building on existing certifications for nonsterile antimicrobial wound dressings [3] - This expansion aligns with the FDA's new Quality Management System Regulation (QMSR) effective February 2026, harmonizing U.S. requirements with ISO 13485 [3] Commitment to Quality - The expanded certification supports Kane's ability to pursue regulatory approvals across multiple jurisdictions and demonstrates its investment in quality systems and operational readiness [4] - The Chief Quality Officer emphasized that compliance with ISO 13485 and MDSAP enhances trust among healthcare providers and patients, ensuring alignment with evolving regulatory expectations [5]

Core Insights - NeoGenomics reported a 10% increase in full-year revenue to $727 million, with clinical revenue growing 15% [1] - The company successfully resolved RaDaR ST patent litigation, enhancing its product offerings [1] Financial Performance - Fourth quarter consolidated revenue rose 11% to $190 million, while full-year consolidated revenue increased 10% to $727 million [1] - The net loss for the fourth quarter decreased by 36% to $10 million, but the full-year net loss increased by 37% to $108 million [1] - Adjusted EBITDA for the fourth quarter was positive at $13 million, a 13% increase, and for the full year, it rose 9% to $43 million [1] Growth Drivers - The company experienced a 23% growth in Next-Generation Sequencing (NGS) in Q4 and 22% for the full year, outpacing market growth [1] - The upcoming clinical launch of the RaDaR ST MRD assay is expected to tap into the $20+ billion molecular residual disease monitoring market [1] Operational Metrics - Average revenue per clinical test increased by 5% to $488, with a 7% growth excluding Pathline tests [1] - Consolidated gross profit for Q4 was $83 million, an 8% increase, leading to a gross profit margin of 43.8% [1] Future Guidance - For FY 2026, the company projects consolidated revenue between $793 million and $801 million, representing a 9% to 10% year-over-year increase [1] - The anticipated net loss for 2026 is expected to range from $63 million to $50 million, a significant improvement from 2025 [1]

Core Viewpoint - Pasithea Therapeutics Corp. is advancing its lead drug candidate, PAS-004, a next-generation macrocyclic oral MEK inhibitor, aimed at treating NF1-associated plexiform neurofibromas and is actively participating in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [1][2]. Company Overview - Pasithea Therapeutics is a clinical-stage biotechnology company focused on the research and development of PAS-004, which targets RASopathies, MAPK pathway-driven tumors, and other diseases [4]. - The company is currently conducting a Phase 1 clinical trial for PAS-004 in advanced cancer patients (NCT06299839) and a Phase 1/1b clinical trial for adult patients with NF1-associated plexiform neurofibromas (NCT06961565) [4]. Event Details - The presentation by CEO Tiago Reis Marques is scheduled for February 26, 2026, from 4:00 to 4:30 PM ET, and will be available for viewing via a live webcast [2][3]. - Management will also be available for one-on-one meetings with qualified investors registered for the conference [2].

Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis [Accessibility Statement] Skip NavigationSAN FRANCISCO, Feb. 17, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced an academic research collaboration with the University of California, San Francisco (UCSF) and Stephen L. Hauser, M.D., Robert A. Fishman Distinguished Professor of Neurology and Director of the UCSF ...

Core Viewpoint - Can-Fite BioPharma Ltd. has announced promising results for its lead drug candidate, namodenoson, in treating obesity, supported by a peer-reviewed study demonstrating its anti-obesity effects and favorable safety profile [1][4][6]. Group 1: Study Findings - The study published in the International Journal of Obesity shows that namodenoson significantly inhibits adipocyte proliferation and lipid droplet accumulation in a dose-dependent manner [4]. - In a murine high-fat diet model, daily oral administration of namodenoson for four weeks resulted in a statistically significant reduction in weight gain compared to placebo-treated controls [4]. - The findings align with previous Phase IIa clinical study results, where namodenoson treatment for three months led to reductions in liver fat and body weight in patients with metabolic dysfunction-associated steatohepatitis (MASH) [3][4]. Group 2: Mechanism of Action - Namodenoson modulates key molecular pathways involved in adipogenesis and inflammation, upregulating adiponectin and suppressing various signaling pathways such as PI3K, NF-κB, Akt, and Wnt/β-catenin [5]. - The drug's mechanism suggests a multi-pathway metabolic approach to obesity treatment [5]. Group 3: Market Potential - The global obesity treatment market is projected to reach $60.5 billion by 2030, with a compound annual growth rate (CAGR) of approximately 22%, driven by increasing disease prevalence and demand for safe, effective oral therapies [7]. - Namodenoson's favorable safety profile and broad patent portfolio position it as a promising candidate in this rapidly growing market [4][6]. Group 4: Company Overview - Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company focused on developing proprietary small molecule drugs for oncological and inflammatory diseases [1][9]. - Namodenoson is currently in advanced clinical development for MASH and is also being evaluated in pivotal trials for advanced liver cancer and pancreatic cancer [8][10].

Core Viewpoint - Arvinas, Inc. is set to review its fourth quarter and full year 2025 financial results and provide a corporate update on February 24, 2026, at 8:00 a.m. ET [1] Company Overview - Arvinas, Inc. is a clinical-stage biotechnology company focused on developing a new class of drugs based on targeted protein degradation [3] - The company utilizes its PROTAC (PROteolysis TArgeting Chimera) platform to create therapies that degrade disease-causing proteins by leveraging the body's natural protein disposal system [3] - Arvinas is advancing multiple investigational drugs through clinical development, including: - ARV-102, targeting LRRK2 for neurodegenerative disorders - ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers - ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma - Vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer [3]

Core Viewpoint - Perspective Therapeutics, Inc. is set to report its full year 2025 financial results and provide a business update on March 16, 2025, after market close [1] Company Overview - Perspective Therapeutics, Inc. specializes in radiopharmaceutical development, focusing on advanced cancer treatments using proprietary technology that employs the alpha-emitting isotope 212Pb to target cancer cells [2] - The company is also developing complementary imaging diagnostics that utilize the same targeting moieties, allowing for personalized treatment and improved patient outcomes through a "theranostic" approach [2] Clinical Development - The company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are currently in Phase 1/2a imaging and therapy trials in the U.S. [3] - Perspective Therapeutics is expanding its regional network of drug product candidate finishing facilities, supported by its proprietary 212Pb generator, to provide patient-ready product candidates for clinical trials and commercial operations [3]

Core Insights - AtaiBeckley Inc. is focused on developing innovative mental health treatments aimed at improving patient outcomes [1][3] - The company will participate in several investor conferences in March, including fireside chats and one-on-one meetings [1][2] Company Overview - AtaiBeckley is a clinical-stage biotechnology company dedicated to creating rapid-acting, durable, and convenient mental health treatments [3] - The company's pipeline includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder [3] - BPL-003 is currently in Phase 3 planning, while VLS-01 and EMP-01 are in Phase 2 clinical development [3] - AtaiBeckley is also working on a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD [3] Upcoming Events - The company will host a fireside chat on March 4 from 11:50 am to 12:20 pm EST in Boston, Massachusetts [5] - One-on-one meetings are scheduled for March 10 in Miami, Florida [5] - Another fireside chat will take place on March 11 from 8:00 am to 8:30 am EST, also in Miami [5]

Core Insights - CollPlant Biotechnologies is strategically positioning its photocurable dermal filler platform to address facial volume loss associated with GLP-1 weight-loss therapies, targeting a growing market of patients experiencing facial fat depletion due to rapid weight loss [1][2] Group 1: Product Development - The photocurable dermal filler is designed to restore facial volume while providing a supportive regenerative matrix that integrates with surrounding tissue [1] - This technology aims to provide immediate structural restoration and support tissue integration, potentially improving skin quality and elasticity over time [1] - CollPlant's filler technology is currently in the preclinical stage, as part of a broader strategy to develop next-generation regenerative aesthetic solutions based on recombinant human collagen (rhCollagen) [1] Group 2: Market Opportunity - The rapid global adoption of GLP-1 therapies is driving increased demand for aesthetic solutions that address changes in facial structure following significant weight loss [1] - There is a growing interest in non-surgical treatments that restore volume while maintaining natural facial dynamics, indicating a shift in patient preferences [1] - CollPlant's regenerative biomaterial platform positions the company to meet this emerging clinical and aesthetic need [1] Group 3: Strategic Partnerships - In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, which is a leader in the dermal filler market [1]

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NYSE: IBRX), a commercial stage immunotherapy company developing next generation therapies that drive immunological memory and restore immune competence, today announced that the Company held productive regulatory discussions with the Saudi Food and Drug Authority (SFDA) in Riyadh, convened under the Saudi-USA Biotech Alliance hosted by the Ministry of Investment of Saudi Arabia (MISA). The engagement advanced two regulatory priorities: (. ...